Edition:
India

Sorrento Therapeutics Inc (SRNE.OQ)

SRNE.OQ on NASDAQ Stock Exchange Capital Market

2.25USD
8 Dec 2017
Change (% chg)

-- (--)
Prev Close
$2.25
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
164,849
52-wk High
$6.05
52-wk Low
$1.50

Chart for

About

Sorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications,... (more)

Overall

Beta: 1.68
Market Cap(Mil.): $137.77
Shares Outstanding(Mil.): 76.54
Dividend: --
Yield (%): --

Financials

BRIEF-Sorrento Therapeutics files for mixed shelf of upto $350 mln

* Sorrento Therapeutics Inc files for mixed shelf of upto $350 million - SEC filing‍​ Source text: [http://bit.ly/2yLg1nW] Further company coverage:

09 Nov 2017

BRIEF-Sorrento Therapeutics- ‍Terminated​ deal with Semnur Pharma to purchase all its issued and outstanding equity

* Sorrento Therapeutics - ‍ co, unit Semnur Pharmaceuticals terminated​ deal by which unit would, purchase all of issued and outstanding equity of Semnur Source text: (http://bit.ly/2xYZewg) Further company coverage:

07 Oct 2017

BRIEF-Sorrento Therapeutics files for resale by selling stockholders of up to 754K shares of common stock - SEC filing‍​

* Sorrento Therapeutics Inc - files for resale by selling stockholders of up to 754,930 shares of common stock - SEC filing‍​ Source text: (http://bit.ly/2xTIxlX) Further company coverage:

05 Oct 2017

BRIEF-FDA acknowledges receipt of Sorrento Therapeutics Inc's NDA for Ztlido

* Fda acknowledges receipt of Sorrento Therapeutics Inc, NDA for Ztlido; PDUFA date set for February 28, 2018

12 Sep 2017

BRIEF-Sorrento Therapeutics submits NDA for Ztlido

* Sorrento Therapeutics Inc submits NDA for Ztlido next-generation lidocaine patch

29 Aug 2017

BRIEF-ABG Management's Yu Fan reports 12.2 pct stake in Sorrento Therapeutics as of July 10

* ABG Management's Yu Fan reports 12.2 percent stake in Sorrento Therapeutics as of July 10 - SEC filing

10 Jul 2017

BRIEF-SORRENTO THERAPEUTICS ANNOUNCES DISMISSAL OF LAWSUITS

* SORRENTO THERAPEUTICS INC SAYS DISMISSAL OF ALL CLAIMS AGAINST SORRENTO AND ITS DIRECTORS CONTAINED IN LAWSUITS BROUGHT BY WILDCAT LIQUID ALPHA, LLC Source text for Eikon: Further company coverage:

15 Jun 2017

BRIEF-Sorrento Therapeutics to contribute immuno-oncology and cellular therapy intellectual property, assets to Celularity

* Sorrento Therapeutics - co, unit executed definitive agreement to contribute certain immuno-oncology and cellular therapy intellectual property, assets to Celularity Source text for Eikon: Further company coverage:

13 Jun 2017

Competitors

Earnings vs. Estimates